TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Ryoncil® Sales Increase 60% in December Quarter to US$35.1M

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Ryoncil® Sales Increase 60% in December Quarter to US$35.1M

Mesoblast Limited reported gross revenue of US$35.1 million for Ryoncil® in Q2 2025, representing a 60% increase from the prior quarter. The company secured a new US$125 million five-year facility with substantially lower costs, enabling repayment of prior senior debt and providing flexibility for strategic partnerships and label expansion efforts.

Insights
JNJ   positive

Mentioned as a top key player developing AI-enabled surgical devices like OTTAVA


MESO   positive

Strong 60% quarter-over-quarter revenue growth for lead product Ryoncil®, successful refinancing with lower-cost capital structure, improved balance sheet flexibility, and upcoming pivotal trial expansion into larger adult market segment demonstrate solid commercial traction and financial improvement.